Dr Bryan Peter Peters, PHARMD | |
21754 Eastmere Ln, Friant, CA 93626-9753 | |
(559) 325-2537 | |
(559) 354-5213 |
Full Name | Dr Bryan Peter Peters |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 21754 Eastmere Ln, Friant, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1649560954 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | RPH 51322 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Bryan Peter Peters, PHARMD 21754 Eastmere Ln, Friant, CA 93626-9753 Ph: (559) 325-2537 | Dr Bryan Peter Peters, PHARMD 21754 Eastmere Ln, Friant, CA 93626-9753 Ph: (559) 325-2537 |
News Archive
Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson's Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
Dean Evans & Associates today announced the official rollout of new versions of their facility scheduling and resource management products. Used at more than 3,600 customer sites in the U.S. and abroad, EMS (Event Management System) software provides powerful tools for helping organizations be more efficient at reserving rooms, resources and personnel for meetings and events, managing resource inventories and communicating details to staff, meeting organizers and attendees.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
› Verified 7 days ago